Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, raised $40 million by offering 3.3 million shares at $12, the low end of the range of $12 to $15. Vaccinex plans to list on the Nasdaq under the symbol VCNX....read more
Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, announced terms for its IPO on Monday. The Rochester, NY-based company plans to raise $45 million by offering 3.3 million shares at a price range of $12 to $15....read more
Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, filed on Monday with the SEC to raise up to $46 million in an initial public offering.
The Rochester, NY-based company was founded in 2001 and plans to list on the ...read more
Vaccinex prices IPO at $12, the low end of the range
Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, raised $40 million by offering 3.3 million shares at $12, the low end of the range of $12 to $15. Vaccinex plans to list on the Nasdaq under the symbol VCNX....read more
Antibody therapy biotech Vaccinex sets terms for $45 million IPO
Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, announced terms for its IPO on Monday. The Rochester, NY-based company plans to raise $45 million by offering 3.3 million shares at a price range of $12 to $15....read more
US IPO Weekly Recap: Filings pick up during an otherwise quiet week
Sign up for a free trial of our premium platform, IPO Pro. Follow us on Twitter (...read more
Antibody therapy biotech Vaccinex files for a $46 million IPO
Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, filed on Monday with the SEC to raise up to $46 million in an initial public offering. The Rochester, NY-based company was founded in 2001 and plans to list on the ...read more